Doheny Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Doheny Asset Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-6,150	Closed	-$252K	–	114
2017 Q3	$252K	Buy	+6,150	New	+$193K	0.12%	100
2017 Q2	–	Sell	-6,150	Closed	-$222K	–	115
2017 Q1	$222K	Hold	6,150	–	–	0.1%	104
2016 Q4	$308K	Hold	6,150	–	–	0.15%	91
2016 Q3	$323K	Hold	6,150	–	–	0.17%	87
2016 Q2	$254K	Hold	6,150	–	–	0.13%	91
2016 Q1	$250K	Hold	6,150	–	–	0.13%	91
2015 Q4	$255K	Buy	+6,150	New	+$206K	0.12%	94

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Doheny Asset Management's FPRX Position: Q4 2017 in Review

Doheny Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2017, closing a stake of 6,150 shares — an estimated $252K sold.

Doheny Asset Management first reported a position in FPRX in Q4 2015 and held it in 7 quarters. The position peaked at $323K in Q3 2016. 137 funds tracked by Wall St. Rank hold FPRX as of Q4 2017.

Doheny Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Doheny Asset Management sold 6,150 Five Prime Therapeutics, Inc. shares in Q4 2017, an estimated $252K.
Doheny Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2015 and held it in 7 quarters.
Doheny Asset Management's Five Prime Therapeutics, Inc. position peaked at $323K in Q3 2016.
137 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2017.

Based on Doheny Asset Management's 13F filing for Q4 2017, filed 15 Feb 2018.